Key Record Dates
| ClinicalTrials.gov Identifier: | NCT06058377 |
|---|---|
| Brief Title: | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer |
| First Submitted : | September 27, 2023 |
| First Submitted that Met QC Criteria : | September 27, 2023 |
| First Posted : | September 28, 2023 |
| Last Update Submitted that Met QC Criteria : | May 9, 2024 |
| Last Update Posted : | May 10, 2024 |